Navigation Links
'Fake Marijuana' Users Showing Up in Emergency Rooms
Date:11/11/2010

By Jenifer Goodwin
HealthDay Reporter

THURSDAY, Nov. 11 --(HealthDay News) -- A form of synthetic marijuana known as "K2" is sending young people to the hospital with racing heart beats, extreme anxiety and hallucinations, toxicologists warn.

In recent months, physicians and toxicologists say more young people have been showing up in emergency rooms after smoking synthetic marijuana. Despite the side effects, K2 is legal in many states, although many state legislators are rushing to pass legislation banning it.

Since the start of 2010, the American Association of Poison Control Centers has received nearly 2,000 reports of people who became ill after smoking K2, compared to about a dozen in 2009. Poison control officials described some of the symptoms as "life-threatening."

K2 is often marketed as incense and sold in packets of herbs laced with synthetic marijuana at "head shops," gas stations, convenience stores and online for about $30 to $40 per three-gram bag. The drug also goes by other names, including Spice, Spice Gold, Spice Diamond, Yucatan Fire, Solar Flare, K2 Summit, Genie, PEP Spice, and Fire n Ice, according to the U.S. Drug Intelligence Center.

While people who smoke K2 think they're going to experience deep relaxation and euphoria, those who end up in the hospital report unpleasant experiences, said Dr. Anthony Scalzo, medical director of the Missouri Poison Center and chief of toxicology at St. Louis University.

"The classic symptoms are agitation, anxiety, racing heart beat, elevated blood pressure," Scalzo said. "And some kids are having very negative psychotropic experiences. One said, 'I felt like I went down to hell'."

In some cases, the drug also causes vomiting, tremors and seizures, according to federal drug abuse agencies.

Scalzo was the first to sound the alarm about K2 earlier this year after seeing a couple of dozen of reports of young people treated at emergency rooms who said they'd smoked K2.

The drug, also sold under the name Happy Shaman Herbs, Smoke, Skunk and Zohai, among others, was developed for study purposes in the mid-'90s in the lab of John Huffman, a Clemson University chemist, who was conducting National Institute on Drug Abuse-supported research on cannabinoids.

The chemical makeup of the drug, which he called JWH-018 and JWH-073, was similar to tetrahydrocannabinol (THC), the active ingredient in marijuana, only considerably more potent.

While THC is a cannabinoid, it's one of many, Huffman said. There are many other substances that interact with the cannabinoid receptors in the brain and other organs, Huffman said.

"These receptors don't exist so that people can smoke marijuana and get high; they play a role in regulating appetite, nausea, mood, pain and inflammation. They may be involved in the development of conditions such as osteoporosis, liver disease and some kinds of cancer," Huffman said. "Synthetic cannabinoids can help us understand these interactions and ultimately this knowledge may contribute to the development of new therapies.

Huffman and his colleagues described JWH-018 and JWH-073 in scientific literature. "Evidently some people have figured out how to make them," Huffman said.

Huffman warned that the drugs were only meant to be used in the lab and were not designed for use in people, Huffman said. "These compounds were not meant for human consumption," Huffman said. "Their effects in humans have not been studied and they could very well have toxic effects. They absolutely should not be used as recreational drugs."

And while the makers of K2 seem to have latched on to JWH-018, many other labs have developed their own synthetic cannabinoids that may also find their way into synthetic marijuana products, Scalzo said.

The K2 craze caught on several years ago Europe, prompting several countries to make synthetic cannabis products illegal.

In the United States, the Drug Enforcement Agency has listed K2 as a "drug or chemical of concern." But because it isn't officially "scheduled," it remains legal under federal law, according to published reports.

Alarmed by the rise in popularity, several states have rushed to outlaw K2. Earlier this year, Kansas became the first state to ban K2. Other states that have outlawed it include Iowa, Missouri, Arkansas, Kentucky, Alabama, Michigan and Illinois (where K2 remains legal until the end of the year). There are similar bills pending in many other states, including Nebraska, North Dakota, Ohio, New York, New Jersey and Louisiana.

Scalzo said the prohibitions don't come a moment too soon. Little is known about the health effects of the drug. But he's heard enough anecdotal reports about strange behavior -- ranging from extreme agitation to withdrawal to a suicide after smoking K2 -- to be concerned.

"This chemical was not meant to be used in any kind of pharmaceutical manner," Scalzo said.

More information

The U.S. National Institute of Drug Abuse has more about synthetic THC.

SOURCES: Anthony Scalzo, M.D., chief of toxicology, St. Louis University, St. Louis, Mo.; John Huffman, Ph.D., research professor, organic chemistry, Clemson University, Clemson, S.C.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Some Fake ADHD to Get Meds, Special Treatment
2. UC studies show marijuana has therapeutic value, reports to legislature
3. International Merchant Advisors Inc. to Open New Wellness Centers With Medical Marijuana Treatment Facilities
4. International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Networks Big Biz Show February 22, 2010 at 1:40 pm PST
5. Marijuana Use Can Up Psychosis Risk
6. International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc.
7. Michigan Medical Marijuana Certification Center Brings Relief to Patients Across Michigan
8. International Merchant Advisors CEO Mel Roseman to Discuss New Wellness Centers and Medical Marijuana Clinic Acquisitions Program Live on Bill Chippas Show Today, March 11th at 6:20 pm EST
9. MarijuanaDoctors.com Launches the First Online Search and Booking Engine for Patients Seeking Medical Marijuana Doctors
10. The Medical Marijuana Industry Finds an Outside-the-Box Solution, "Inside the Box" With GrowOp Technology
11. First Retail Branded Edible Medical Marijuana Product Line Introduced at San Francisco Trade Show
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Fake Marijuana' Users Showing Up in Emergency Rooms 
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... herbal-based and non-steroidal skincare products, was awarded as winners of American Dreams & ... This competition was hosted jointly by HSN and Good Housekeeping. , Steven ...
(Date:3/23/2017)... VA (PRWEB) , ... March ... ... Evaluation Reports: Complying with European Guidelines and the New MEDDEV 2.7/1 Rev. ... 3:00 p.m. ET, http://www.fdanews.com/mdclineval                  , How will the new EU ...
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare Solutions unveils the ... 21st annual Compliance Institute on March 26-28 in National Harbor, Maryland. ... chart types with a comprehensive set of features including built-in workflow, interactive audit ...
(Date:3/23/2017)... ... ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous power ... Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures which ... new book presents actual events in the life of her family, which validate her ...
(Date:3/23/2017)... ... March 23, 2017 , ... “My Journey Through Heaven”: the true-life ... infinitely more profound faith of God’s promise of Heaven for His people. “My Journey ... each day with his wife, three children and six grandchildren living and doing for ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") ... is pleased to announce that its majority-owned subsidiary, ... U.S. Food and Drug Administration (FDA) for the ... tablets in the 12.5 mg and 25 mg ... equivalent of the branded product Xenazine ® ...
(Date:3/23/2017)... , March 23, 2017 ReNeuron ... its CTX cells in chronic stroke patients, despite not meeting ... primary outcome measure, the Action Research Arm Test (ARAT). As ... to a pivotal controlled clinical study in 2017. Beyond CTX, ... (RP) trial in 2017 and Phase I data from its ...
(Date:3/23/2017)... 2017 The Board of Directors of NeuroVive ... Meeting, which is to take place on Thursday, April 27, 2017, ... Lund, Sweden . ... Please see the attached notification, which is being announced within ... NeuroVive Pharmaceutical AB (Publ) The Board Of Directors About ...
Breaking Medicine Technology: